Wegovy Side Effects: Nausea, Hair Loss & Timeline (2026)

01

The most common Wegovy side effects

In placebo-controlled weight-management trials, gastrointestinal reactions were the most frequently reported Wegovy side effects, and they were clearly dose-related. According to the FDA-approved Wegovy label, reactions occurring in ≥5% of patients were nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation (belching), hypoglycemia in people with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.

The label reports the following incidence for Wegovy 2.4 mg versus placebo in adults (N=2,116 vs 1,261):

(Source: FDA Wegovy prescribing information, Table 2. Individual experience varies.)

Overall, 73% of Wegovy-treated patients reported a GI reaction versus 47% on placebo.

Crucially, most GI symptoms were transient, clustered around dose escalation, and only a minority led to stopping the drug — about 6.8% of patients discontinued Wegovy for adverse reactions versus 3.2% on placebo, most commonly for nausea, vomiting, or diarrhea.

Wegovy nausea

Nausea is the single most common Wegovy side effect — reported by roughly 44% of adults in trials versus 16% on placebo.

It typically peaks in the first days after starting or after a dose increase, then settles as your body adjusts.

Practical strategies widely recommended by clinics such as Cleveland Clinic: eat smaller, more frequent meals, eat slowly and stop at the first feeling of fullness, favor bland, low-fat foods, and sip fluids between meals rather than with them.

Greasy, fried, and very sweet foods tend to make Wegovy nausea worse.

If nausea is disruptive, some clinicians prescribe a short course of an anti-nausea medicine around dose increases. (Deep-dive: how to manage GLP-1 nausea.)

Wegovy hair loss

Unlike the Ozempic label, the Wegovy label explicitly lists hair loss (alopecia) — reported by 3% of adults on Wegovy versus 1% on placebo. Importantly, dermatologists generally attribute this shedding not to a direct toxic effect of semaglutide but to telogen effluvium: a temporary, reversible form of hair shedding triggered by the rapid weight loss and nutritional shift that come with effective treatment.

Because Wegovy reaches a higher dose and drives more weight loss than Ozempic, hair thinning is reported more often.

Shedding usually appears about two to four months after the trigger and typically recovers on its own as weight stabilizes.

Eating enough protein and a nutrient-varied diet — easy to under-do when appetite drops — helps protect hair. Persistent or patchy loss warrants a check for iron or other deficiencies.

Vomiting, diarrhea, and constipation

Vomiting (24%) and diarrhea (30%) are common on Wegovy and can cause a real problem: dehydration. Because Wegovy also blunts thirst and appetite, it is easy to under-drink.

Persistent vomiting or diarrhea that keeps you from holding down fluids is a reason to call your clinician — partly because severe dehydration can, in rare cases, trigger acute kidney injury (see serious effects below).

Constipation (24%) stems from the same slowed gut motility; more fiber, fluids, and movement usually help, but severe cramping with bloating and vomiting can signal a blockage.

Other common effects

People also report belching, heartburn/reflux, gas, bloating, fatigue, headache, dizziness, and injection-site reactions. These are usually mild.

02

How long do Wegovy side effects last?

For most people, the common gastrointestinal side effects are temporary. Nausea and related symptoms most often ease within a few weeks of starting Wegovy or of each dose increase, as the body adjusts — a pattern clinics describe as typical for GLP-1 medicines, though some people feel effects longer.

Because side effects cluster around dose changes, a slow, gradual dose escalation is the single most effective way to limit them, which is why the manufacturer builds in a multi-week titration schedule that begins at a low, non-therapeutic 0.25 mg starter dose.

The Wegovy label's titration is stepwise: 0.25 mg in weeks 1–4, then 0.5 mg, 1 mg, and 1.7 mg at four-week intervals, reaching the 2.4 mg maintenance dose at about week 17. The label notes that if a patient does not tolerate a step, the escalation can be delayed by four weeks — a decision for your prescriber, not a self-adjustment.

If a side effect is still severe after several weeks, or you are losing weight faster than intended, that is a signal to talk with your prescriber, who may hold or reduce your dose.

Do not change your own dose without medical guidance.

03

Dose-dependence: why 2.4 mg matters

Wegovy side effects are strongly dose-dependent, and Wegovy titrates to a higher target dose than Ozempic (2.4 mg vs up to 2 mg).

This is the main reason gastrointestinal side effects are generally reported more often with Wegovy. It is also why the prescribing information uses a stepwise titration rather than starting at the full dose.

The most reliable predictor of how you will tolerate Wegovy is how quickly the dose is increased, not any personal "toughness." If a step is hard, prescribers can slow the ramp.

04

Serious Wegovy side effects and warnings

These are less common but important, and they are why Wegovy is prescription-only and medically supervised.

Pancreatitis

The Wegovy label warns that acute pancreatitis — including rare fatal and hemorrhagic or necrotizing cases — has been observed with GLP-1 receptor agonists.

The classic sign is severe, persistent abdominal pain, often in the upper abdomen and sometimes radiating to the back, with or without vomiting.

Manufacturer guidance is explicit: stop the medicine and seek care promptly.

Gallbladder problems and gallstones

Treatment with Wegovy is associated with an increased occurrence of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis); in adult weight-loss trials cholelithiasis was reported by about 1.6% of Wegovy-treated patients, some requiring surgery.

Warning signs include pain in the upper-right abdomen, fever, yellowing of the skin or eyes (jaundice), and clay-colored stools.

Delayed gastric emptying, severe GI reactions, and aspiration risk

Wegovy slows stomach emptying by design, but in some people this becomes problematic.

The label warns of severe gastrointestinal reactions and lists ileus (intestinal blockage) among reactions.

A related concern is a rare risk of pulmonary aspiration during general anesthesia or deep sedation, because food may remain in the stomach — so tell your care team you take Wegovy before any surgery or procedure with sedation.

Boxed warning: thyroid C-cell tumors

Semaglutide carries the FDA's strongest boxed warning for thyroid C-cell tumors, based on findings in rodents; whether this applies to humans is not known. Wegovy is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a lump in the neck, trouble swallowing, shortness of breath, or persistent hoarseness.

Kidney injury, hypoglycemia, heart rate

There have been postmarketing reports of acute kidney injury — some needing dialysis — mostly in people who became dehydrated from nausea, vomiting, or diarrhea.

On its own Wegovy carries a low hypoglycemia risk, but the risk rises with insulin or a sulfonylurea in people with type 2 diabetes.

The label also flags a modest increase in heart rate and, for people with type 2 diabetes, diabetic retinopathy monitoring.

Mood and suicidal thoughts

As a weight-management product, the Wegovy label instructs clinicians to monitor for depression, suicidal thoughts, or unusual mood changes and to discontinue if they emerge.

For added context: after formal 2024 reviews, both the U.S. FDA and the European Medicines Agency concluded the available evidence does not support a causal link between GLP-1 receptor agonists and suicidal or self-harm thoughts.

Still, report any new or worsening mood changes to your clinician.

05

When to seek care: Wegovy red-flag table

When in doubt, call your clinician or emergency services — this table is a guide, not a substitute for professional judgment.

06

Wegovy vs Ozempic side effects: same molecule, higher dose

Wegovy and Ozempic are both semaglutide, so they share the same side-effect profile. The differences are in dose and indication:

Because Wegovy titrates to a higher dose, gastrointestinal side effects — and labeled hair loss — are generally reported more often with Wegovy.

For the diabetes-dose profile, see our Ozempic side effects guide.

07

Practical ways to reduce Wegovy side effects

1. Go slow. Follow the titration schedule; never rush to a higher dose on your own.
2. Eat smaller, more frequent, lower-fat meals and stop at the first sign of fullness.
3. Hydrate — sip water through the day, especially with any vomiting or diarrhea.
4. Limit greasy, fried, very sweet, and heavily processed foods, which worsen nausea.
5. Add fiber and move your body to counter constipation.
6. Prioritize protein and gradual weight loss to protect muscle and reduce hair shedding.
7. Track your symptoms, doses, and meals so patterns are visible for your next visit.
8. Report red-flag symptoms immediately — don't "wait it out."

Because Wegovy side effects cluster around specific days and doses, a simple daily log of what you feel, when you dosed, and what you ate makes conversations with your clinician far more useful.

This is exactly what the Havit app is built to make effortless — log your dose, meals, and how you feel, and see your own patterns over time. (It's a tracking companion, not a medical device — always defer to your clinician.)

08

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

Roughly 20–40% of the weight lost on GLP-1 therapy can come from lean (muscle) tissue rather than fat (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

The most common Wegovy side effects

Related articles